References of "Radermecker, Régis"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPompes à insuline, capteurs et activité physique. Existe t il des recommandations?
RADERMECKER, Régis ULg

in Diabète et Obésité (2014)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailQu'apportent les nouvelles recommandations américaines à propos de la prise en charge des dyslipidémies en prévention cardiovasculaire ? Comparaison avec les recommandations européennes et belges
Descamps, O; Rietzschel, E; Langlois, M et al

in Louvain Medical (2014), 133(1), 26-35

Les dernières recommandations américaines concernant la prise en charge des dyslipidémies en prévention cardiovasculaire ont soulevé de nombreuses questions par leurs différences avec nos approches ... [more ▼]

Les dernières recommandations américaines concernant la prise en charge des dyslipidémies en prévention cardiovasculaire ont soulevé de nombreuses questions par leurs différences avec nos approches habituelles. Entre autres, elles ont éradiqué la nécessité de « cible » de LDL-C à atteindre en fonction du niveau de risque cardiovasculaire et ont proposé plutôt une stratégie basée sur l’intensité de la réduction relative du LDL-C. L’examen critique et la comparaison des recommandations font apparaitre, toutefois, plus de similitudes que de différences, tout en encourageant à repenser certains aspects de notre pratique et à raviver notre motivation pour le plus grand bien des patients. [less ▲]

Detailed reference viewed: 60 (5 ULg)
Full Text
Peer Reviewed
See detailA propos de l'hémoglobine glycquée: les limites de son interprétation
Sepulchre, E; LUTTERI, Laurence ULg; CAVALIER, Etienne ULg et al

in Revue Médicale de Liège (2014), 69(9), 497-503

Determining the level of glycated haemoglobin, in particular its major fraction called HbA1c, is an attractive tool in the management of diabetic patients. In fact, it provides a global evaluation of the ... [more ▼]

Determining the level of glycated haemoglobin, in particular its major fraction called HbA1c, is an attractive tool in the management of diabetic patients. In fact, it provides a global evaluation of the glycemic control’s level through the past 8-12 weeks. However, this tool must be used with caution. First of all, it does not allow to examine the glycemic kinetics since it represents a glycemic average. Secondly, it does not allow to appreciate the glycemic evolution through the full day. This dosage needs then sometimes to be complemented by fingersticks blood glucose testing. Last but not least, caution is advised in interpreting the results because a number of physiological, pathological and technical factors might interfere with HbA1c measurement. It is therefore important that physicians keep a critical view of the values obtained. The paper reviews the different methods used to determine the level of glycated haemoglobin and their limitations. It also emphasizes the medical situations in which over- and under-estimation of the real HbA1c value could occur. It does not address the specific issue of the new expression values of HbA1c in mmol/mol instead of %. Moreover, the medical situations in which over- and under estimation of the real HbA1c value could occur will be described. [less ▲]

Detailed reference viewed: 6 (1 ULg)
Full Text
See detailLes inhibiteurs du cotransporteur du glucose SGLT rénal: une nouvelle classe thérapeutique dans le diabète de type 2
Sepulchre, Edith; RADERMECKER, Régis ULg

in Journal de Cardiologie [= JDC] = Tijdschrift voor Cardiologie [= TVC] (2013), 25(8), 429-434

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
Begin once trial investigators; RADERMECKER, Régis ULg

in Diabetic Medicine : A Journal of the British Diabetic Association (2013)

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailComparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
BEGIN Once Long Trial Investigators; RADERMECKER, Régis ULg

in Diabetic Medicine : A Journal of the British Diabetic Association (2013)

Detailed reference viewed: 25 (0 ULg)
Full Text
Peer Reviewed
See detailRecommandations europeennes pour la prise en charge du diabete, du pre-diabete et des maladies cardio-vasculaire. 1ere partie. Gestion du diabete et des facteurs de risque cardio-vasculaire.
Scheen, André ULg; RADERMECKER, Régis ULg; PHILIPS, Jean-Christophe ULg et al

in Revue medicale de Liege (2013), 68(11), 585-92

The patient with prediabetes or diabetes has a high or very high risk of cardiovascular diseases.We summarize the recent guidelines jointly published by the European Society of Cardiology and the European ... [more ▼]

The patient with prediabetes or diabetes has a high or very high risk of cardiovascular diseases.We summarize the recent guidelines jointly published by the European Society of Cardiology and the European Society for the Study of Diabetes. In this first article, we focus mainly on the preventive approaches of cardiovascular diseases in patients with prediabetes or (type 1 or type 2) diabetes. The crucial importance of a global multifactorial strategy is emphasized and the target levels of various risk factors are updated. The management of these cardiovascular complications in presence of diabetes will be considered in a second article. [less ▲]

Detailed reference viewed: 42 (8 ULg)
Full Text
See detailRegard sur la peau diabétique et ses méhins.
PIERARD, Gérald ULg; RADERMECKER, Régis ULg; SCHEEN, André ULg

in Revue de l'Association Belge du Diabète (2013), 56

La peau exprime certains changements qui sont souvent proportionnels à la durée et la sévérité du diabète. La plupart des composants de la peau sont affectés à des degrés divers, parfois cliniquement ... [more ▼]

La peau exprime certains changements qui sont souvent proportionnels à la durée et la sévérité du diabète. La plupart des composants de la peau sont affectés à des degrés divers, parfois cliniquement imperceptibles, parfois très sévères et invalidants. [less ▲]

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailVitamin D and type 2 diabetes mellitus: Where do we stand?
CAVALIER, Etienne ULg; DELANAYE, Pierre ULg; SOUBERBIELLE, J.-C. et al

in Diabètes & Métabolism (2011), 37(4), 265-72

AIMS: In-vitro and observational studies have established a link between vitamin D deficiency and different type 2 diabetes outcomes (insulin resistance, insulin secretion, glucose intolerance). Although ... [more ▼]

AIMS: In-vitro and observational studies have established a link between vitamin D deficiency and different type 2 diabetes outcomes (insulin resistance, insulin secretion, glucose intolerance). Although the number of randomized controlled trials vs placebo is small, vitamin D (VTD) has been shown to prevent increases in glucose concentration and insulin resistance, enhance insulin sensitivity and reduce systolic blood pressure in type 2 diabetic patients. METHODS: In this review, we have focused on the potential mechanisms that might explain the association between VTD and type 2 diabetes mellitus (T2DM). We have also evaluated the different epidemiological and observational studies on the topic, as well as the various interventional studies. RESULTS: Although the in vitro studies appear to be promising in explaining the link between VTD metabolism and T2DM, the results of in vivo studies are conflicting. This could be related to differences in their methodological approaches. CONCLUSION: Although more studies are needed to confirm the role of VTD in the treatment of T2DM, there is nevertheless enough evidence at this time to suggest a need to maintain 25-OH vitamin D levels in T2DM patients around 30ng/mL over the course of a year. [less ▲]

Detailed reference viewed: 62 (8 ULg)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2
SCHEEN, André ULg; RADERMECKER, Régis ULg; ERNEST, Philippe ULg et al

in Revue Médicale Suisse (2011), 7(306), 1621-1629

Detailed reference viewed: 28 (7 ULg)
Full Text
See detailMonitoring continu du glucose: où en est on?
RADERMECKER, Régis ULg

Conference (2011, May 21)

Présentation des données actuelles sur le monitoring continu du glucose en Diabétologie.

Detailed reference viewed: 25 (6 ULg)
Full Text
See detailDiabète et autocontrôle
RADERMECKER, Régis ULg

in Revue de l'Association Belge du Diabète (2011), 54(2), 18-21

Detailed reference viewed: 66 (12 ULg)
Peer Reviewed
See detailTight Glycaemic control and nutrition: A comparison of two protocols
Suhaimi, F; Le Compte, AJ; Preiser, JC et al

in Proceedings of the Centre for Bio-Engineering One Day Conference 2010 (2010)

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailWhat makes tight glycemic control tight? The impact of variability and nutrition in two clinical studies.
Suhaimi, Fatanah; Le Compte, Aaron; Preiser, Jean-Charles ULg et al

in Journal of Diabetes Science and Technology (2010), 4(2), 284-98

INTRODUCTION: Tight glycemic control (TGC) remains controversial while successful, consistent, and effective protocols remain elusive. This research analyzes data from two TGC trials for root causes of ... [more ▼]

INTRODUCTION: Tight glycemic control (TGC) remains controversial while successful, consistent, and effective protocols remain elusive. This research analyzes data from two TGC trials for root causes of the differences achieved in control and thus potentially in glycemic and other outcomes. The goal is to uncover aspects of successful TGC and delineate the impact of differences in cohorts. METHODS: A retrospective analysis was conducted using records from a 211-patient subset of the GluControl trial taken in Liege, Belgium, and 393 patients from Specialized Relative Insulin Nutrition Titration (SPRINT) in New Zealand. Specialized Relative Insulin Nutrition Titration targeted 4.0-6.0 mmol/liter, similar to the GluControl A (N = 142) target of 4.4-6.1 mmol/liter. The GluControl B (N = 69) target was 7.8-10.0 mmol/liter. Cohorts were matched by Acute Physiology and Chronic Health Evaluation II score and percentage males (p > .35); however, the GluControl cohort was slightly older (p = .011). Overall cohort and per-patient comparisons (median, interquartile range) are shown for (a) glycemic levels achieved, (b) nutrition from carbohydrate (all sources), and (c) insulin dosing for this analysis. Intra- and interpatient variability were examined using clinically validated model-based insulin sensitivity metric and its hour-to-hour variation. RESULTS: Cohort blood glucose were as follows: SPRINT, 5.7 (5.0-6.6) mmol/liter; GluControl A, 6.3 (5.3-7.6) mmol/liter; and GluControl B, 8.2 (6.9-9.4) mmol/liter. Insulin dosing was 3.0 (1.0-3.0), 1.5 (0.5-3), and 0.7 (0.0-1.7) U/h, respectively. Nutrition from carbohydrate (all sources) was 435.5 (259.2-539.1), 311.0 (0.0-933.1), and 622.1 (103.7-1036.8) kcal/day, respectively. Median per-patient results for blood glucose were 5.8 (5.3-6.4), 6.4 (5.9-6.9), and 8.3 (7.6-8.8) mmol/liter. Insulin doses were 3.0 (2.0-3.0), 1.5 (0.8-2.0), and 0.5 (0.0-1.0) U/h. Carbohydrate administration was 383.6 (207.4-497.7), 103.7 (0.0-829.4), and 207.4 (0.0-725.8) kcal/day. Overall, SPRINT gave approximately 2x more insulin with a 3-4x narrower, but generally non-zero, range of nutritional input to achieve equally TGC with less hypoglycemia. Specialized Relative Insulin Nutrition Titration had much less hypoglycemia (<2.2 mmol/liter), with 2% of patients, compared to GluControl A (7.7%) and GluControl B (2.9%), indicating much lower variability, with similar results for glucose levels <3.0 mmol/liter. Specialized Relative Insulin Nutrition Titration also had less hyperglycemia (>8.0 mmol/liter) than groups A and B. GluControl patients (A+B) had a approximately 2x wider range of insulin sensitivity than SPRINT. Hour-to-hour variation was similar. Hence GluControl had greater interpatient variability but similar intrapatient variability. CONCLUSION: Protocols that dose insulin blind to carbohydrate administration can suffer greater outcome glycemic variability, even if average cohort glycemic targets are met. While the cohorts varied significantly in model-assessed insulin resistance, their variability was similar. Such significant intra- and interpatient variability is a further significant cause and marker of glycemic variability in TGC. The results strongly recommended that TGC protocols be explicitly designed to account for significant intra- and interpatient variability in insulin resistance, as well as specifying or having knowledge of carbohydrate administration to minimize variability in glycemic outcomes across diverse cohorts and/or centers. [less ▲]

Detailed reference viewed: 39 (7 ULg)
Full Text
See detailDiabète, convention et trajet de soins
RADERMECKER, Régis ULg

in Actualités Innovations Médecine (2010), (12), 21-22

Detailed reference viewed: 26 (1 ULg)
Full Text
Peer Reviewed
See detailManagement of blood glucose in patients with stroke.
Radermecker, Régis ULg; Scheen, André ULg

in Diabètes & Métabolism (2010), 36S3

Stroke is a leading cause of death worldwide and the most common cause of long-term disability amongst adults, more particularly in patients with diabetes mellitus and arterial hypertension. Increasing ... [more ▼]

Stroke is a leading cause of death worldwide and the most common cause of long-term disability amongst adults, more particularly in patients with diabetes mellitus and arterial hypertension. Increasing evidence suggests that disordered physiological variables following acute ischaemic stroke, especially hyperglycaemia, adversely affect outcomes. Post-stroke hyperglycaemia is common (up to 50% of patients) and may be rather prolonged, regardless of diabetes status. A substantial body of evidence has demonstrated that hyperglycaemia has a deleterious effect upon clinical and morphological stroke outcomes. Therefore, hyperglycaemia represents an attractive physiological target for acute stroke therapies. However, whether intensive glycaemic manipulation positively influences the fate of ischaemic tissue remains unknown. One major adverse event of management of hyperglycaemia with insulin (either glucose-potassium-insulin infusions or intensive insulin therapy) is the occurrence of hypoglycaemia, which can also induce cerebral damage. Novel insights into post-stroke hyperglycaemia management have been derived from continuous glucose monitoring systems (CGMS). This article aims: 1) to describe the adverse effects of hyperglycaemia following acute ischaemic stroke and the risk associated with iatrogenic hypoglycaemia; 2) to summarise the evidence from current glucose-lowering treatment trials; and 3) to show the usefulness of CGMS in both non-diabetic and diabetic patients with acute stroke. [less ▲]

Detailed reference viewed: 37 (7 ULg)